<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332280</url>
  </required_header>
  <id_info>
    <org_study_id>AMT/P2CA/001</org_study_id>
    <secondary_id>LC003AURON2005</secondary_id>
    <nct_id>NCT00332280</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo</brief_title>
  <official_title>A Prospective, Randomised, Multicenter Phase II/III Clinical Trial to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Auron Healthcare GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Auron Healthcare GmbH</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer
      patients with advanced disease.

      The primary evaluation criterion is clinical benefit response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include patients with a variety of solid tumors (i.e. esophageal, colon,
      pancreatic, bronchial, gastric, hepatocellular, gall bladder, prostate and gynaecological
      carcinomas.)

      The clinical benefit response - CBR, is an end point that provides a clinical measure for
      symptom improvement in patients. The key evaluation parameters for CBR will be assessment of
      pain, the ability to perform daily activities and weight change.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy. Stopped at first interim evaluation point
  </why_stopped>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in clinical benefit response</measure>
    <time_frame>Jan 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Jan 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Jan 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>January 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30])</measure>
    <time_frame>Jan 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Jan 2010</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>AMT2003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMT2003</intervention_name>
    <arm_group_label>AMT2003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer confirmed by histology or cytology

          -  At least one measurable lesion

          -  Advanced disease refractory to standard therapy or for which no standard therapy
             exists

          -  Life expectancy at least 3 months

        Exclusion Criteria:

          -  Known secondary neoplasia or central nervous system (CNS) metastases, acute or chronic
             leukemia, lymphoma or multiple myeloma

          -  Body weight below 45 kg

          -  Female patients who are pregnant or breast feeding or adults of reproductive potential
             not employing effective birth control methods

          -  Concurrent severe or uncontrolled medical disease

          -  Acute or chronic liver disease

          -  Confirmed diagnosis of HIV

          -  Insulin dependent diabetes mellitus/abnormal glucose tolerance test (GTT)/latent
             diabetes mellitus type I or II

          -  Chemotherapy or radiotherapy less than 4 weeks prior to entry

          -  Surgery less than 2 weeks prior to entry (or not recovered from effects of surgery)

          -  Participation in a clinical trial less than 30 days prior to entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim Drevs, PD Dr. Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic SanaFontis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinicki Centar Univerziteta Sarajevo - Klinika za gastroenterohepatologiju</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic SanaFontis</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.alpiniainstitute.com</url>
    <description>Alpinia Institute now legally responsible for the study</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2006</study_first_submitted>
  <study_first_submitted_qc>May 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2006</study_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>solid tumors</keyword>
  <keyword>clinical benefit</keyword>
  <keyword>quality of life</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>colon cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>liver cancer</keyword>
  <keyword>gall bladder cancer</keyword>
  <keyword>prostate cancer</keyword>
  <keyword>gynecological cancer</keyword>
  <keyword>lung cancer</keyword>
  <keyword>Tumors of GI tract, prostate and gynaecological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

